The remote patient monitoring (RPM) sector is undergoing a transformative phase, driven by regulatory updates, artificial intelligence (AI) integration, and a surge in consumer-grade wearable adoption. As healthcare systems grapple with chronic disease burdens and workforce shortages, RPM has moved from a niche telehealth add-on to a cornerstone of value-based care delivery. This article examines the latest policy shifts, technology breakthroughs, and expert perspectives shaping the industry through early 202 5.

CMS Final Rule Expands Reimbursement for RPM and Remote Therapeutic Monitoring

In a landmark development, the Centers for Medicare & Medicaid Services (CMS) finalized its 2025 Physician Fee Schedule in November 2024, introducing significant changes to RPM billing codes. For the first time, CMS has allowed separate payment for initial patient setup and education for RPM devices (CPT code 98980) when performed by clinical staff under general supervision, eliminating the prior requirement for direct physician involvement. More notably, CMS expanded the definition of “physiologic data” to include continuous glucose monitors, blood pressure cuffs, and pulse oximeters, while adding new codes for remote therapeutic monitoring (RTM) that cover medication adherence and therapy response.

“This is a clear signal that CMS views RPM not as a convenience but as a medically necessary service,” said Dr. Elena Rodriguez, a health policy analyst at the Brookings Institution. “The expansion of RTM codes, which now include audio-only patient engagement for behavioral health, acknowledges that not all monitoring requires high-bandwidth video. It’s a pragmatic step toward equity in digital health access.”

Industry analysts estimate that the new rules could increase RPM adoption by 30% among small-to-mid-sized practices, which previously found billing complexity prohibitive. However, CMS also imposed a new requirement: RPM devices must be “medically necessary” and data must be reviewed at least every 16 days, a threshold that some vendors argue is logistically challenging for low-acuity populations.

AI-Powered Predictive Analytics Moves from Pilot to Standard Practice

The most significant technological trend in RPM is the integration of machine learning algorithms that do more than transmit data—they predict decompensation events. In January 2025, two major RPM platforms—VitalConnect and Biofourmis—announced partnerships with academic medical centers to deploy AI models that analyze heart rate variability, respiratory rate, and activity patterns to forecast hospital readmissions up to 10 days in advance.

“We are moving from reactive monitoring to proactive intervention,” stated Dr. Marcus Chen, Chief Medical Officer of Biofourmis. “Our latest model, trained on 2.3 million patient-days of data, achieved an AUC of 0.87 for predicting acute heart failure exacerbations. That’s clinically actionable. The challenge now is workflow integration—ensuring that alerts reach the right clinician at the right time, without alert fatigue.”

A peer-reviewed study published inJAMA Network Openin December 2024 corroborated this trend, showing that AI-enhanced RPM reduced 30-day readmissions by 23% in a cohort of 4,500 Medicare beneficiaries with COPD and congestive heart failure. Notably, the study found that the AI’s benefit was most pronounced in patients over 75, a demographic often excluded from digital health trials.

However, experts caution against over-reliance on algorithms. Dr. Sarah Whitfield, a geriatrician at Johns Hopkins, notes, “AI can flag trends, but it cannot assess social determinants—like food insecurity or lack of transportation—that often drive deterioration. The best programs pair AI with human case managers who conduct video visits or phone check-ins. The technology is a force multiplier, not a replacement.”

Wearable Proliferation and Consumer-Grade Devices Enter Clinical Workflows

The consumer wearables market—led by Apple Watch, Smart Scales, and Samsung—has reached a tipping point for clinical legitimacy. In October 2024, the FDA granted De Novo clearance to the Samsung Galaxy Watch’s irregular heart rhythm notification feature, which uses photoplethysmography to detect atrial fibrillation. This follows Apple’s earlier clearance for its ECG app and the more recent approval of sleep apnea detection on the Apple Watch Series 10.

What’s new in 2025 is the formal integration of these consumer devices into physician-prescribed RPM programs. Major EHR vendors, including Epic and Cerner, now offer plug-ins that allow clinicians to receive data from patients’ own smartwatches, provided the patient consents and the device meets minimal accuracy standards. This “bring-your-own-device” model could dramatically lower the cost barrier for RPM, which traditionally required proprietary, prescription-only hardware costing $150–$500 per unit.

“We’re seeing a shift in mindset,” said Jennifer Alvarez, Vice President of Product Strategy at ResMed, which recently launched a hybrid program combining its medical-grade sleep monitors with data from consumer wearables. “Patients already wear these devices. The question is not whether we can monitor them, but whether we can make the data interoperable and clinically meaningful. We’ve solved the connectivity problem; the remaining challenge is data overload.”

Indeed, the volume of data generated by consumer wearables is staggering. A typical patient produces over 1,000 data points per day. Without robust filtering and clinical decision support, this deluge can overwhelm primary care teams. Several startups, including Huma and Current Health, have developed “clinician dashboards” that aggregate data into a single risk score, flagging only actionable anomalies.

Regulatory and Privacy Landscape Tightens

While reimbursement expands, privacy regulations are becoming stricter. The Office for Civil Rights (OCR) at the U.S. Department of Health and Human Services issued a new bulletin in December 2024 clarifying that RPM data collected by consumer wearables, when transmitted to a healthcare provider, falls under HIPAA jurisdiction. This closes a loophole that previously allowed some vendors to sell de-identified data to third parties.

“The bulletin was overdue,” commented privacy lawyer and former OCR official, David Kessler. “But it creates a compliance burden for wearable manufacturers who never anticipated being HIPAA business associates. We’re advising clients to either enter into BAA agreements with health systems or anonymize data at the edge—on the device itself—before transmission.”

Internationally, the European Union’s Medical Device Regulation (MDR) has continued to force consolidation in the RPM market. Smaller device makers, unable to afford the cost of MDR certification (estimated at €200,000–€500,000 per device), have either exited the market or been acquired. This has led to a concentration of market share among a few large players, which some industry observers argue could stifle innovation. In contrast, the U.S. FDA’s software precertification program, though still pilot, has expedited approval for AI-based RPM algorithms.

Expert Outlook: The Next 18 Months

Looking ahead, three trends dominate expert predictions. First, the integration of RPM with home-based acute care (Hospital-at-Home) is expected to accelerate, as CMS continues to waive the requirement that patients must be within 30 miles of a brick-and-mortar hospital. Second, the adoption of RPM in behavioral health is poised for explosive growth, following the expansion of RTM codes to cover medication management for psychiatric conditions. Third, the emergence of “digital biomarkers”—using voice, gait, and typing speed to detect cognitive decline—will open new frontiers for early intervention in neurodegenerative diseases.

Dr. Rodriguez sums up the sentiment: “RPM is no longer a pilot project. It’s a standard of care for chronic disease management. The next frontier is not technology—it’s scaling the workforce and redesigning payment models to reward outcomes, not just device usage. Those who solve that puzzle will define the future of healthcare delivery.”

As the industry moves forward, one thing is clear: remote patient monitoring has evolved from a pandemic-era stopgap to a permanent, intelligent, and increasingly personalized pillar of modern medicine. Stakeholders—from device manufacturers to clinicians to policymakers—must now collaborate to ensure that this powerful tool reduces disparities rather than widening them.